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Abstract
Background: The HLA-B*35-Px allele has been associated with rapid disease progression in HIV-1 infection, in contrast to
the HLA-B*35-Py allele.
Methodology/Principal Findings: Immune responses to two HLA-B*35 restricted HIV-1 specific CTL epitopes and their
variants were followed longitudinally during early HIV-1 infection in 16 HLA-B*35+ individuals. Subjects expressing HLA-
B*35-Px alleles showed no difference in response to the consensus epitopes compared to individuals with HLA-B*35-Py
alleles. Surprisingly, all the HLA-B*35-Px+ individuals responded to epitope-variants even in the absence of a consensus
response. Sequencing of the viral population revealed no evidence of variant virus in any of the individuals.
Conclusions/Significance: This demonstrates a novel phenomenon that distinguishes individuals with the HLA-B*35-Px
rapid progressing allele and those with the HLA-B*35-Py slower progressing allele.
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Introduction
Host genetics are known to have a major influence on HIV-1
disease progression [1,2,3,4,5]. For example, HLA-B*57 and -
B*27 are two MHC class I alleles which have been associated with
slower progression to AIDS [6,7]. At the other end of the
spectrum, HLA-B*35 alleles have been shown to be associated
with more rapid disease progression [8].
HLA-*B35 alleles can be segregated into B*35-Px and -Py
alleles, which differ by a number of amino acids located in the
HLA binding groove [9]. These differences result in different
peptide binding preferences. HLA-B*35-Py molecules preferen-
tially bind peptides with a proline (P) at anchor residue 2 and a
tyrosine (Y) at position 9. HLA-B*35-Px molecules also bind
peptides with a proline at anchor residue 2, but can accept a much
broader range of residues at position 9. However, both HLA-
B*35-Px and -Py molecules are capable of binding epitopes that do
not fit the conventional PY motif (Los Alamos Database, http://
www.hiv.lanl.gov/). The most common B*35-Py alleles are
B*3501 and B*3508, while the B*35-Px alleles include B*3502/
3503/3504/5301.
The marked difference in HIV-1 disease progression of
individuals expressing either HLA B*35-Py or -Px alleles is not
understood. The overall magnitude of the HIV-1-specific CD8+ T
cell immune response does not differ between individuals
expressing either -Px or Py alleles [10]. However, this was
measured at the level of the total CD8+ T cell response, and thus
specific responses to individual epitopes were not differentiated.
Measuring responses to specific epitopes may be critical in
understanding the differences in disease progression between
individuals with these alleles. We therefore set out to analyze T cell
responses to two HLA-B*35 restricted HIV-1 epitopes in both
HLA-B*35 -Px and -Py allele expressing individuals.
Methods
This study was approved by the UCSF Institutional Review
Board.
Human Study Subjects and Blood Samples
Peripheral blood mononuclear cells (PBMC) samples were
obtained from HIV-1 infected subjects, from the University of
California San Francisco (UCSF) OPTIONS project (Table 1).
HLA-A type, CD4 count and HIV-1 viral load were determined
for each subject (Table 1). All samples were processed with Ficoll-
Paque PLUS (Amersham Biosciences, Pittsburgh, PA) and PBMC
were stored frozen in 10% DMSO in fetal bovine serum prior to
subsequent analysis. Written informed consent and approval for
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Institutional Review Board.
ELISPOT assay
Quantification of HIV-specific T-cell responses using thawed
viable PBMC was performed using the IFN-c ELISPOT assay.
Briefly, each well of a 96-well plate (Millipore MAHAS4510,
Bedfort, MA) was coated with 50 ml of anti-IFN-c mAb (Mabtech,
Stockholm, Sweden) at 5 mg/ml. After incubation, each well was
washed and blocked with 10% FCS in RPMI (Cellgro). PBMC
(1610
5–2610
5) were added to duplicate wells and peptides were
added at varying concentrations to the cells. As a positive control,
the mitogen phytohemagglutinin (PHA) was used at 4 mg/ml, and
wells with only media added were used as a negative control. After
overnight incubation (14–16 hours) at 37uC, plates were washed
with phosphate-buffered saline (PBS). Biotinylated anti-IFN-c
mAb 7-B6-1 (Mabtech) was added at 1 mg/ml, and incubated at
37uC for 1 hr. Plates were washed with PBS +0.1% Tween 20 and
treated with streptavidin-bound alkaline phosphatase. After 1 h
incubation, plates were washed with PBS +0.1% Tween 20 and
developed using Alkaline Phosphatase Substrate Kit III (Vector
Laboratories, Burlingame, CA). IFN-c spot-forming units (SFUs)
were visualized and counted using an AID EliSpot reader
(Autoimmun Diagnostika GMBH, Germany). Spots were stan-
dardized to SFU/10
6 PBMC. Spots formed in the presence of
media alone were considered non-specific background and
subtracted from the SFU in stimulated wells. The wells where
the number of SFU was greater than two times background or
greater than 50 SFU/106 PBMCs, which ever was higher, were
considered as responses.
Viral Load Assessment
Plasma HIV-1 viral load was determined by bDNA (Bayer).
Results
T cell responses from 16 HLA-B*35+ HIV-1 infected in-
dividuals were analyzed using the IFN-c enzyme-linked immuno-
spot (ELISpot) assay over the first years of infection. All the
patients were from the University of California San Francisco
Table 1. Clinical parameters, average CD4 and viral load (VL)
were generated from across the entire study window.
B*35 Study ID HLA-A HLA-B
Average
CD4
Average
VL
Subject 1 1 2407 3505 5107 401 52744
Subject 2 2501 6801 702 3503 829 21644
Px Subject 3 11 11 18 35 520 57035
Subject 4 201 2402 3502 3924 492 15011
Subject 5 2902 3101 3503 4403 826 3897
Subject 7 1 2901 3518 8101 616 53262
Subject 8 1 3 3528 51 728 59894
Subject 9 1101 7401 3501 5101 1067 18713
Subject 10 nt nt 3501 4901
PY Subject 11 301 2601 3501 4001 597 72495
Subject 12 201 2402 702 3501 993 45539
Subject 13 201 1101 3501 4001 811 10324
Subject 14 201 1101 3501 4402 645 4904
Subject 15 201 1101 3501 5101 757 33454
Subject 16 301 2402 3501 5701 430 19961
PxPY Subject 6 1101 6801 3501 3505 705 20828
doi:10.1371/journal.pone.0010249.t001
Figure 1. A representative example, from subject 1, of longitudinal CD8+ T cell IFN-c responses to the TY9 epitope (solid green
bars) and VY10 (solid orange bars). All subjects showed similar responses towards both epitopes that waxed and waned over the course of the
study window.
doi:10.1371/journal.pone.0010249.g001
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PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10249Figure 2. CD8+ T cell IFN-c responses to both consensus epitopes (solid bars, TY9 green and VY10 orange), and variant epitopes
(TY9 variants green, checkered or stripped bars, and VY10 variant orange checkered bars). Representative examples of longitudinal
responses are shown for HLA-B*35 -Px+ Subjects 1 (A) and 2 (B), and HLA-B*35 -Py+ Subject 8 (C). CD8+ T cell IFN-c responses from Subject 6, who
expressed both HLA-B*35 -Px and -Py alleles (D). HLA-B*35 -Px+ individuals did not display unusual CD4 counts or viral loads, a representative
example shown from Subject 1 (E).
doi:10.1371/journal.pone.0010249.g002
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expressed an HLA-B*35-Px allele, and 10 individuals expressed
an HLA-B*35-Py allele. One individual expressed both HLA
B*35-Px and -Py alleles. No significant difference in CD4+ T cell
count (p=0.44) or plasma viral loads (p=0.7) were observed
between the two groups, as determined by two-tailed Mann
Whitney test analysis (Table 1).
CD8+ T cell responses were determined by a standard IFN-c
ELISpot assay [12,13,14], using thawed peripheral blood mono-
nuclear cells (PBMC). All spot numbers were normalized to
numbers of IFN-c spot-forming units (SFU) per 10
6 PBMCs.
Responses were determined by subtracting the SFU values from
medium control wells from the peptide induced response. All
experimental assays and analyses were conducted blinded to the
individual’s specific HLA-B*35 allele.
PBMC were screened against two HLA-B*35 restricted HIV-
1-Pol derived epitopes: TVLDVGDAY and VPLDEDFRKY
[15,16]. At one or more time points we observed a loss of an
epitope specific-response in all individuals tested, an example is
s h o w ni nF i g .1 .H o w e v e r ,t h e r ew a sn oc l e a rd i f f e r e n c ei nt h e
size or number of epitope-specific responses between the either
HLA-B*35-Px+ or -Py+ individuals (data not shown). HLA-
B*35 -Px+ individuals did not display unusual CD4 counts
or viral loads, a representative example shown from Subject 1
(E).
Unexpectedly, all the HLA-B*35-Px+ individuals made respons-
es to all the peptides tested. Strikingly, they were able to recognize
the variant epitope in the absence of a consensus response at one or
more time points tested, as shown for 2 patients (Subject 1 and
Subject 2) (Fig. 2A and 2B). However, HLA-B*35-Py+ individuals
never recognized the variant epitopes alone at any of the time
points tested (Fig. 2C). Individuals who made responses solely to
variant epitopes at one time point or more, showed no unexpected
clinical characteristics at these or any other time points (Fig. 2E).
We observed no difference in the magnitudes of responses target-
ing HLA-B*35 specific epitopes in either HLA-B*35 -Px+ or -Py+
individuals. Both groups were able to recognize and respond to
epitope variants. However, only the HLA-B*35 -Px+ individuals
were able to respond to variants in the absence of a wild-type
response.
The ability of the five HLA-B*35 -Px+ individuals to make
solely variant-specific responses implied that they may harbor
variant HIV-1 within their viral population. To test this, their
HIV-1 reverse transcriptase, codons 40 through 247, were
sequenced using the TRUGENE HIV-1 RNA genotyping kit
and OpenGene system software for sequence analysis (Siemens
Medical Solutions Diagnostics) [17,18]. At no time point tested,
were any variants of the consensus epitopes seen (Table 2).
Interestingly, one individual from the cohort, Subject 6,
expressed both HLA-B*35 -Px and -Py alleles. This individual
also responded solely to the variant epitopes at one time point
(Fig. 2D). Again, this individual did not display variant viruses
within their viral population. This suggests that the HLA-B*35-Px
effect dominates over the HLA-B*35-Py influence. Lost or weak
responses have been shown to be rescued by blocking PD-1 - PD-
1L interactions. However, PD-1 - PD-1L blockage did not
improve the restore absent responses in any of the individuals
tested (data not shown).
Discussion
HIV-1 responses associated with delayed disease progression
have been shown to be efficiently cross-reactive with epitope
variants [19]. We hypothesized that the individuals with HLA-
B*35-Px alleles, associated with rapid disease progression, would
have limited recognition of epitope variants. Thus, we predicted
that HLA-B*35 -Py+ individuals would exhibit T-cell responses to
variant peptides more frequently than individuals with HLA-B*35-
Px alleles. Naturally occurring variants of both epitopes were
tested: TVLDVGDAF, TILDVGDAY, and IPLDEDFRKY.
HLA-B*35-Py+ individuals never recognized the variant epitopes
alone at any of the time points tested. Unexpectedly, all the HLA-
B*35-Px+ individuals made responses to all the peptides tested,
and only the HLA-B*35 -Px+ individuals were able to respond to
variants in the absence of a wild-type response, and no evidence
for variant epitope viruses. We have thus named the responses to
these epitopes ‘‘vestigial’’ CTL epitopes, as the responses are made
to sequences that appear to be no longer present.
Due to the non-standard motifs of these epitopes, HLA
tetramers could not be made and therefore individual CD8+ T
cell populations could not be studied with this technology.
This leaves open the question of whether the responses to the
variant epitopes, made in the absence of a consensus epitope
response, are unique responses specifically targeting the variant
epitopes or cross-reactive responses that at these time points
d i dn o tr e s p o n dt ot h ec o n s e n s u se p i t o p e .W i t h o u tv a r i a n t
viruses within the viral population to drive the variant-specific
responses, it is intriguing to speculate on how specific re-
sponses could be generated and maintained. One possibility is
that these variant epitopes are heteroclitic [20]; capable of
stimulating CD8+ T cells to a greater magnitude than the
consensus epitope against which they were originally generated.
Since the two HLA-B*35 allele subtypes differ in their binding
grooves, they may present epitopes in different orientations.
Thus, at the time points where only responses to the variant
(vestigial) epitopes are seen, the greater stimulus provided by
the variant epitope could induce IFN-c expression from
otherwise unresponsive CD8+ Tc e l l s .T h i si sa na r e at h a t
has been study in greater depth in the cancer immunity field
[21,22,23].
This unusual phenomenon demonstrates a distinct difference
between the HLA-B*35 alleles associated with rapid progression
and those that are not. What role this plays in disease progression
remains to be elucidated. Here, we provide the first evidence to
our knowledge, of a difference in CD8+ T cell responses restricted
to the two HLA-B*35 allele subtypes.
Table 2. HIV-1 Pol Sequencing of HLA-B*35 -Px allele
expressing individuals.
Study ID
Estimate
weeks Post
Infection T V L D V G D A Y V P L D E D F R K Y
Subject 1 653 .............K.....
Subject 2 92 .............KX ....
Subject 3 182 ...................
Subject 4 10 ..............N ....
1 3 4 ..............N ....
Subject 5 30 .............K.....
Subject 6 10 ...................
1 3 ...................
3 7 ...................
6 1 .............XX ....
doi:10.1371/journal.pone.0010249.t002
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